Intravenous versus intratracheal administration of mesenchymal stem cells in a mouse model of asthma

doi:10.3969/j.issn.2095-4344.2015.28.010

Abstract

Abstract:

BACKGROUND: Several studies have demonstrated that mesenchymal stem cells exhibit strong immunomodulation on allergic asthma. However, there are no reports to compare therapeutic effects under different administration ways.

OBJECTIVE: To examine the immunomodulatory effects of MSCs via different administration routes on asthmatic mice.

METHODS: Seventy-two Balb/c mice experienced three independent tests, and 24 mice were selected for each test. Twenty-four mice were randomly divided into four groups (n=6): control group, model group, intravenous treatment group and intratracheal treatment group. The mouse model of asthma was induced via intraperitoneal injection of ovalbumin at 1, 7, 14 days and 30-minute aerosol inhalation of ovalbumin at 22-26 days. In the latter two groups, mesenchymal stem cells were injected intravenously (200 μL, 5×10⁹/L) or intratracheally (50 μL, 2×10⁹/L) into the mice at 1 day before aerosol inhalation.

RESULTS AND CONCLUSION: Compared with the control group, the airway inflammatory response was significantly increased in the model group. Intravenous administration of mesenchymal stem cells significantly alleviated the symptoms of allergic airway inflammation, including the airway hyperreactivity, the inflammatory cell counting in the bronchoalveolar lavage fluid, inflammatory cell infiltration in the lung tissue. Meanwhile, the levels of Th2 type cytokines in the bronchoalveolar lavage fluid and IgE in serum also decreased after intravenous administration of mesenchymal stem cells. However, the intratracheal application of mesenchymal stem cells did not exhibit the similar effects. Intravenous, not intratracheal, application of mesenchymal stem cells can exert immunomodulatory effects through the blood circulation.
中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Asthma, Mesenchymal Stem Cells, Inflammation, Trachea

CLC Number:

R394.2

Yao Yin, Guo Jie-bo, Deng Xue-quan, Sun Yue-qi, Fu Qing-ling. Intravenous versus intratracheal administration of mesenchymal stem cells in a mouse model of asthma [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(28): 4478-4484.

Figures/Tables 3

References

[1] Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-192.
[2] Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-454.
[3] Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838-3843.
[4] Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367-372.
[5] Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24(1):74-85.
[6] Sun YQ, Deng MX, He J, et al. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cells. 2012;30(12):2692-2699.
[7] 李斌恺,赖克方,洪燕华,等.支气管哮喘小鼠气道反应性无创检测方法的建立[J].国际呼吸杂志,2009,29(1):5-8.
[8] Baïz N, Annesi-Maesano I. Is the asthma epidemic still ascending? Clin Chest Med. 2012;33(3):419-429.
[9] Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. 2006;355(21):2226-2235.
[10] Orihara K, Dil N, Anaparti V, et al. What's new in asthma pathophysiology and immunopathology? Expert Rev Respir Med. 2010;4(5):605-629.
[11] Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2015;15(1):57-65.
[12] Papaioannou AI, Kostikas K, Zervas E, et al. Control of asthma in real life: still a valuable goal? Eur Respir Rev. 2015; 24(136):361-369.
[13] In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004;22(7):1338-1345.
[14] Gronthos S, Mankani M, Brahim J, et al. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A. 2000;97(25):13625-13630.
[15] Nadri S, Soleimani M. Comparative analysis of mesenchymal stromal cells from murine bone marrow and amniotic fluid. Cytotherapy. 2007;9(8):729-737.
[16] Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012;10(6):709-716.
[17] Kim N, Cho SG. New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation. Int J Stem Cells. 2015;8(1):54-68.
[18] Prockop DJ. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells. 2013;31(10): 2042- 2046.
[19] Ahmad T, Mukherjee S, Pattnaik B, et al. Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. EMBO J. 2014; 33(9):994-1010.
[20] Nemeth K, Keane-Myers A, Brown JM, et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci U S A. 2010;107(12):5652-5657.
[21] François M, Galipeau J. New insights on translational development of mesenchymal stromal cells for suppressor therapy. J Cell Physiol. 2012;227(11):3535-3538.
[22] Weiss DJ. Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012. Ann Am Thorac Soc. 2013;10(5): S45-97.
[23] Bonfield TL, Koloze M, Lennon DP, et al. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol. 2010;299(6):L760-770.
[24] 韩灵,孙悦奇,付清玲,等.呼吸道变应性炎性反应小鼠模型的建立[J].中华耳鼻咽喉头颈外科杂志,2013,48(3):224-228.
[25] Abreu SC, Antunes MA, de Castro JC, et al. Bone marrow-derived mononuclear cells vs. mesenchymal stromal cells in experimental allergic asthma. Respir Physiol Neurobiol. 2013;187(2):190-198.
[26] Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54-63.
[27] Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5): 759-765.
[28] Galipeau J. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15(1): 2-8.
[29] Kretlow JD, Jin YQ, Liu W, et al. Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol. 2008;9:60.
[30] Weiss DJ, Bertoncello I, Borok Z, et al. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc. 2011;8(3):223-272.
[31] Kips JC, Anderson GP, Fredberg JJ, et al. Murine models of asthma. Eur Respir J. 2003;22(2):374-382.
[32] Gao P, Zhou Y, Xian L, et al. Functional effects of TGF-β1 on mesenchymal stem cell mobilization in cockroach allergen-induced asthma. J Immunol. 2014;192(10): 4560-4570.
[33] Cho KS, Park HK, Park HY, et al. IFATS collection: Immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells. 2009; 27(1):259-265.
[34] Su WR, Zhang QZ, Shi SH, et al. Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms. Stem Cells. 2011;29(11):1849-1860.
[35] Lewkowich IP, Herman NS, Schleifer KW, et al. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med. 2005;202(11):1549-1561.
[36] Pellerin L, Jenks JA, Bégin P, et al. Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res. 2014;58(2-3):358-368.
[37] Cho KS, Park MK, Kang SA, et al. Adipose-derived stem cells ameliorate allergic airway inflammation by inducing regulatory T cells in a mouse model of asthma. Mediators Inflamm. 2014; 2014:436476.
[38] 李建国,颛孙永勋,冉丕鑫,等.骨髓间充质干细胞对哮喘小鼠CD4+CD25+调节性T细胞及气道炎症的影响[J].中国组织工程研究与临床康复,2008,12(47):9302-9305.
[39] Ge X, Bai C, Yang J, et al. Intratracheal transplantation of bone marrow-derived mesenchymal stem cells reduced airway inflammation and up-regulated CD4?CD25? regulatory T cells in asthmatic mouse. Cell Biol Int. 2013; 37(7):675-686.
[40] Ge X, Bai C, Yang J, et al. Effect of mesenchymal stem cells on inhibiting airway remodeling and airway inflammation in chronic asthma. J Cell Biochem. 2013;114(7):1595-1605.
[41] Kapoor S, Patel SA, Kartan S, et al. Tolerance-like mediated suppression by mesenchymal stem cells in patients with dust mite allergy-induced asthma. J Allergy Clin Immunol. 2012; 129(4):1094-1101.